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Neuromedin S (NMS) is a neuropeptide identiﬁed as another endogenous ligand for two
orphan G protein-coupled receptors, FM-3/GPR66 and FM-4/TGR-1, which have also been
identiﬁed as types 1 and 2 receptors for neuromedinU structurally related toNMS.Although
expression of NMSmRNA is foundmainly in the brain, spleen, and testis, the distribution of
its peptide has not yet been investigated. Using a newly prepared antiserum, we developed
a highly sensitive radioimmunoassay for rat NMS. NMS peptide was clearly detected in the
rat brain at a concentration of 68.3± 3.4 fmol/gwetweight, but it was hardly detected in the
spleen and testis. A high content of NMS peptidewas found in the hypothalamus, midbrain,
and pons–medulla oblongata, whereas abundant expression of NMS mRNA was detected
only in the hypothalamus. These differing distributions of the mRNA and peptide suggest
that nerve ﬁbers originating from hypothalamic NMS neurons project into the midbrain,
pons, or medulla oblongata. In addition, abundant expression of type 2 receptor mRNA
was detected not only in the hypothalamus, but also in the midbrain and pons–medulla
oblongata. These results suggest novel, unknown physiological roles of NMS within the
brainstem.
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INTRODUCTION
Neuromedin S (NMS) is a neuropeptide originally isolated by
our group from the rat brain as an additional endogenous lig-
and for neuromedin U (NMU) receptors types 1 (NMUR1) and
2 (NMUR2), which were previously identiﬁed as the orphan
G protein-coupled receptors FM-3/GPR66 and FM-4/TGR-1,
respectively (Mori et al., 2005). In rats, NMS and NMU are
structurally related peptides composed respectively of 36 and 23
amino-acid residues (Brighton et al., 2004; Mori et al., 2005). They
have an identicalC-terminal amidated seven-residue sequence that
is essential for their agonist activity. NMS and NMU precursors
are encoded by separate genes mapped to human chromosomes
2q11.2 and 4q12, respectively (Mori et al., 2005). Because these
genes are under different transcriptional control, the mRNAs of
NMS and NMU have different patterns of distribution (Brighton
et al., 2004; Mori et al., 2005), indicating that they have different
physiological roles despite having the same agonist effect on their
receptors. Expression of NMS mRNA is observed mainly in the
brain, spleen, and testis, and the highest level of expression is
found in the hypothalamus (Mori et al., 2005). In the rat brain,
NMS mRNA is expressed predominantly in the suprachiasmatic
nucleus (SCN) of the hypothalamus, although low-level expres-
sion of NMS mRNA is also found in other hypothalamic nuclei,
such as the arcuate nucleus (ARC),paraventricular nucleus (PVN),
and supraoptic nucleus (SON; Mori et al., 2005). In contrast to the
mRNA distribution, the distribution of the NMS peptide in the
brain has not yet been elucidated.
Because of the high level expression of NMS mRNA in the
hypothalamus, there has been a focus on the role of NMS in the
brain. The functions of NMS in the brain have been validated
by intracerebroventricular (ICV) administration of the peptide
to rats: ICV-administered NMS causes a phase shift in circa-
dian rhythm (Mori et al., 2005), suppresses food intake (Ida et al.,
2005), reduces urine volume (Sakamoto et al., 2007), increases
milk secretion (Sakamoto et al., 2008), and elevates plasma lev-
els of luteinizing hormone (Vigo et al., 2007). The activity of
NMS is approximately 10 times as great as that of NMU in
the brain, although ICV-administered NMU induces the same
responses (Nakahara et al., 2004; Ida et al., 2005; Mori et al., 2005;
Sakamoto et al., 2007, 2008). These ﬁndings suggest that NMS
plays important roles in the brain. However, it is not certain
whether these actions described above are the physiological roles
of NMS. Interesting results have been obtained by ICV admin-
istration of anti-NMS antibody to rats to neutralize the activity
of endogenous NMS. In contrast to the actions induced by NMS
administration, ICV pretreatment with anti-NMS IgG, but not
anti-NMU IgG, blocks the suppression of food intake induced
by both ICV and intraperitoneally administered leptin in rats
(Nakahara et al., 2010), and ICV administration of anti-NMS anti-
serum suppresses suckling-induced milk ejection in lactating rats
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(Sakamoto et al., 2008), suggesting that endogenous NMS plays
physiological roles in the regulation of food intake and milk ejec-
tion. However, there is no anatomical evidence supporting these
roles in the brain: NMS mRNA expression levels are low in the
ARC, PVN, and SON in the hypothalamus (Mori et al., 2005),
even though these nuclei are involved in the control of feeding
behavior and release of oxytocin, a hormone important for milk
ejection. Therefore, to understand completely the physiological
role of NMS, it is necessary to elucidate the neural circuits formed
by NMS-producing neurons in the brain.
Here, to clarify the physiological signiﬁcance of NMS, we ana-
lyzed the regional distribution of NMS in the rat brain at the
peptide level. We established a highly sensitive radioimmunoassay
(RIA) speciﬁc for rat NMS by using a newly prepared anti-
serum. We then characterized NMS-immunoreactive molecules
separated by reversed-phase high performance liquid chromatog-
raphy (RP-HPLC) and determined the NMS content of the brain
and other tissues. An examination of both NMS content and NMS
mRNA expression in the various regions of the brain suggested
that NMS neurons project directly from the hypothalamus to the
brainstem.
MATERIALS AND METHODS
PREPARATION OF ANTI-RAT NMS ANTISERA
[Cys21]-rat NMS[1-20], a C-terminally Cys-extended rat NMS
fragment (positions 1–20), was synthesized and then conjugated
to maleimide-activated mariculture keyhole limpet hemocyanin.
Anti-rat-NMS serum (batch OB1321-1) was obtained from a
Japanese white rabbit after 10 weekly subcutaneous injections of
conjugate with adjuvant; a second batch (OB1321-2) was obtained
from another rabbit in the sameway. The titers of the antisera were
determined by RIA.
RADIOIODINATION OF TRACER LIGAND
A tracer ligand, [Tyr21]-rat NMS[1-20], was synthesized and then
radioiodinated by using the lactoperoxidase method (Washimine
et al., 1994). After radioiodination, monoiodinated tracer was
puriﬁed by RP-HPLC on a COSMOSIL 5C18-AR-II column
(4.6 × 150 mm; Nacalai Tesque, Japan). The puriﬁed tracer was
stored at −30◦C after the addition of bovine serum albumin at a
concentration of 0.1%.
RIA FOR RAT NMS
The RIA for rat NMS was performed by using the method used for
ghrelin, with minor modiﬁcations (Hosoda et al., 2000). Each RIA
incubation mixture was composed of 100 μl of standard rat NMS
or unknown sample in RIA buffer (50 mM Na2HPO4, 80 mM
NaCl, 25 mM EDTA, 0.5% Triton X-100, 0.5% bovine serum
albumin, 0.05% NaN3, pH 7.4) and 100 μl antiserum diluted with
RIA buffer containing 3.1% dextran T40. OB1321-2 anti-rat-NMS
antiserum was used at a ﬁnal dilution of 1/295,000. After a 24-h
incubation, 18,000 cpm of [125I-Tyr21]-rat NMS[1-20] in 100 μl
of RIA buffer containing 3.1% dextran T40 was added. Bound
and free tracers were separated by precipitation with polyethylene
glycol (PEG). After an additional 24-h incubation, 100 μl of 1%
γ-globulin in precipitation buffer [50 mM phosphate buffer (pH
7.4) containing 80 mM NaCl and 0.05% NaN3] and 500 μl of
16% PEG-6000 in precipitation buffer were added. The solution
was then mixed vigorously and incubated for 15 min. The bound
tracer was precipitated by centrifugation at 1500 g for 20 min,
and then the free tracer was removed by aspiration. All proce-
dures described above were performed at 4◦C. The radioactivity in
the precipitation was counted with a γ-counter ARC-600 (Aloka,
Japan).
PREPARATION OF TISSUE EXTRACTS FOR RIA
All procedures using animal experimentswere performed in accor-
dance with the Japanese Physiological Society’s guidelines for
animal care and the National Cerebral and Cardiovascular Center
Research Institute Guide for the Care and Use of Experimental
Animals. Ten-week-old male Wistar rats were maintained under
12 h light/dark cycles (light on from7:00 to 19:00). Food andwater
were provided ad libitum except during the fasting experiments.
The brains were sampled during the light period at ZT6 (Zeitgeber
time, ZT; ZT0 is lights on and ZT12 is lights off) from free-fed and
48 h-fasted rats, and during the dark period at ZT18 from free-
fed rats. Immediately after decapitation of rats, the brain, spleen,
and testis were resected. The brain was dissected into the cerebral
cortex, cerebellum, hippocampus–thalamus–striatum, hypothala-
mus,midbrain, and pons–medulla oblongata by using the method
of Glowinski and Iversen (1966). After being weighed, each tissue
was minced and then boiled for 5 min in 5× volumes of water.
After being cooled, acetic acid was added to make a ﬁnal concen-
tration of 1 M, and then the boiled tissue was homogenized with
a Polytron homogenizer (Kinematica, Switzerland). The super-
natant of the extract, obtained after a 10-min centrifugation for
at 14,000 g, was concentrated by evaporation and then subjected
to precipitation with acetone at a concentration of 66% acetone.
After removal of precipitates, the supernatant was evaporated to
remove the acetone, and then loaded onto a Sep-Pak C18 car-
tridge (Waters, USA) equilibrated with 0.1% triﬂuoroacetic acid
(TFA). After the cartridge had been washed with 10% acetoni-
trile (CH3CN) in 0.1% TFA, the absorbed material was eluted
with 60% CH3CN in 0.1% TFA, lyophilized, and dissolved in RIA
buffer. Portions of samples, equivalent to 20–300 mg wet weight,
were subjected to RIA.
The cerebrospinal ﬂuid was collected from three anesthetized
12-week-old male Wistar rats, and then subjected to Sep-Pak
puriﬁcation.
CHROMATOGRAPHIC CHARACTERIZATION OF IMMUNOREACTIVE
NMS IN RAT BRAINS
Immediately after peptide extraction, a portion of sample equiva-
lent to 1.2 g wet weight of whole brain was separated by RP-HPLC
on a Symmetry 300 C18 column (3.9 × 150 mm; Waters, USA),
with a linear gradient from 10 to 60% of CH3CN in 0.1% TFA for
40min at a ﬂow rate 1ml/min. Thepuriﬁed cerebrospinal ﬂuidwas
also subjected to RP-HPLC under the same conditions. The elu-
ates were collected everyminute, evaporated, and then lyophilized.
The portions of eluate equivalent to 0.5 g wet weight of tissue and
130 μl of cerebrospinal ﬂuid were subjected to RIA for rat NMS.
Synthetic rat NMS was also applied to the same RP-HPLC sys-
tem to compare the retention time with that of immunoreactive
(ir)-NMS.
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QUANTITATIVE REVERSE TRANSCRIPTION–POLYMERASE CHAIN
REACTION
The brains were sampled from 10-week-old male Wistar rats and
various brain regions were dissected as described above. RNA
was isolated by using TRIzol reagent (Ambion, USA). Reverse
transcription was performed with a QuantiTect reverse transcrip-
tion kit (Qiagen, USA). Quantitative PCR was conducted with
a LightCycler system (Roche, USA) using a SYBR Premix Ex
Taq kit (TaKaRa, Japan). The primer set used for rat NMS was
5′-CTCATCTGTGGTCTGCAAAGAG-3′ and 5′-GCATACAGAA-
GCAGTAGATGAC-3′, and for rat NMUR1 was 5′-CTCAGTCCA-
CTCTATGTACC-3′ and 5′-AGAAGAGCAGTATGGTCGTC-3′,
and for rat NMUR2 was 5′-ACTTGAACAGCACAGAGGAG-3′
and 5′-TTCAAAGTCTGATGTCGGAC-3′. Known amounts of rat
NMS, NMUR1, and NMUR2 cDNA were used to obtain a stan-
dard curve. The data were normalized against total RNA quantity,
wet weight of tissues, or 36B4 level.
RESULTS
RIA FOR RAT NMS
To generate speciﬁc antibodies, the N-terminal fragment (posi-
tions 1–20) of rat NMS was used as antigen, because this region
has no sequence homology to other known peptides includ-
ing rat NMU, a structurally related peptide (Figure 1A). Two
types of antisera were obtained; antiserum OB1321-2 exhibited
a titer against [125I-Tyr21]-rat NMS[1-20] approximately 17 times
higher than OB1321-1 (Figure 1B). Therefore, the OB1321-2
antiserum was used in the subsequent experiments. On the stan-
dard RIA curve, the half-maximum inhibition of [125I-Tyr21]-rat
NMS[1-20] binding to antibody by rat NMS was 6.2 fmol/tube,
and the peptide was detectable at a low level of 0.25 fmol/tube
(Figure 1C). The intra- and inter-assay variations were 3.1 and
3.8%, respectively. This antiserum had no cross-reactivity with rat
NMU (Figure 1C) as well as neuropeptide Y, somatostatin, pitu-
itary adenylate cyclase activating polypeptide, vasoactive intestinal
polypeptide, calcitonin gene-related peptide, adrenocorticotropic
hormone, α-melanocyte-stimulating hormone, and orexin-A,
which are abundantly present in the hypothalamus (data not
shown).
In rats, apparent expression of NMS mRNA is found in
the brain, spleen, and testis (Mori et al., 2005). Therefore, we
quantiﬁed NMS peptide in these tissues. The dilution curve gen-
erated from whole-brain extract paralleled the standard curve
(Figure 1C), and the concentration of NMS in rat whole brain
was 68.3 ± 3.4 fmol/g wet weight (mean ± SEM, n = 3). A small
amount of ir-NMS was detected in the cerebrospinal ﬂuid of rats.
However, its concentration was not determined, because the value
was outside of the range of the standard curve. On the other hand,
speciﬁc ir-NMS was hard to detect in the spleen and testis (data
not shown).
CHROMATOGRAPHIC CHARACTERIZATION OF ir-NMS
IN RAT WHOLE BRAIN
The molecular forms of ir-NMS found in the extract of rat whole
brain were characterized by RIA coupled with RP-HPLC. More
than 90% of ir-NMS was eluted as a single peak, with a retention
time (20–21min) identical to that of synthetic ratNMS (Figure 2).
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FIGURE 1 | Characterization of antisera for rat neuromedin S (NMS).
(A) Structural comparison of rat NMS and rat neuromedin U (NMU).
Structure conserved in the two peptides is shaded. The box indicates the
sequence used as antigen peptide to obtain antisera speciﬁc for rat NMS.
(B) Speciﬁc binding curves of antisera. [125I-Tyr21]-rat NMS[1-20] was
incubated with serially diluted OB1321-1 (closed circles) and OB1321-2
(open circles) antisera, and then co-precipitated with antibody in a
concentration-dependent manner. (C) Standard curve of radioimmunoassay
for rat NMS using antiserum OB1321-2. [125I-Tyr21]-rat NMS[1-20] binding
to antibody was displaced by increasing concentrations of rat NMS (open
circles) but not rat NMU (closed circles). B/B0 means tracer bound/tracer
bound in zero standards. Inset shows the inhibition of tracer ligand binding
to antibody by diluted rat brain extract (open squares).
A very minor ir-NMS was also detected at a retention time of 18–
20min; this corresponded to that observed for oxidizedNMS (data
not shown). Non-speciﬁc immunoreactivity was not observed in
any other eluted fractions.
On the other hand, ir-NMS in the cerebrospinal ﬂuid was also
eluted at a retention time identical to that of synthetic rat NMS
(data not shown).
REGIONAL DISTRIBUTION OF ir-NMS AND NMS
mRNA IN RAT BRAIN
The rat brain was dissected into six parts, and both the
NMS contents and the NMS mRNA expression levels in these
regions were then determined. The highest concentration of ir-
NMS was observed in the midbrain (286.5 ± 26.6 fmol/g wet
weight, mean ± SEM), followed by the pons–medulla oblongata
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FIGURE 2 | Representative reversed-phase high performance liquid
chromatography (RP-HPLC) profile of neuromedin S (NMS)
immunoreactivity in rat brain. Peptide extract (equivalent to 1.2 g wet
weight) from rat whole brain (A) and synthetic rat NMS (B) were applied to
RP-HPLC under the same conditions. Black bars indicate immunoreactive
NMS detected by radioimmunoassay (A). Elution position of rat NMS is
indicated by the arrow (B).
(208.8 ± 18.7 fmol/g wet weight) and hypothalamus (196.2 ±
15.2 fmol/g wet weight; Figure 3). Non-speciﬁc immunoreactivity
was not found in these brain regions by RIA coupled with RP-
HPLC (data not shown). Low levels of ir-NMS were detected in
the other brain regions.
Abundant expression of NMS mRNA was found only in the
hypothalamus (4.69 ± 0.52 copies/ng total RNA, mean ± SEM);
low levels of mRNA expression were observed in the other regions
(Figure 4). Normalization of the mRNA levels against the wet
weight of tissues or 36B4 expression did not change this mRNA
expression proﬁle in the rat brain (data not shown).
REGIONAL DISTRIBUTION OF NMUR1 AND NMUR2 mRNA
IN RAT BRAIN
To elucidate the regional distribution of NMS receptor in rat
brain, the mRNA expression level of NMUR1 and NMUR2
was analyzed by quantitative PCR (Figure 5). NMUR1 mRNA
was widely distributed throughout the brain with low level
of expression (approximately 0.8 copies/ng total RNA). On
the other hand, abundant expression of NMUR2 mRNA was
observed not only in the hypothalamus (7.27 ± 0.81 copies/ng
total RNA, mean ± SEM), but also in the thalamus–striatum–
hippocampus (3.72 ± 1.11 copies/ng total RNA), midbrain
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FIGURE 3 | Regional distribution of immunoreactive neuromedin S
(ir-NMS) in rat brain. Concentrations of ir-NMS in various brain areas were
quantiﬁed by radioimmunoassay. The brains were sampled during the light
period. Data represent means ± SEM of three rats.
(4.20 ± 0.16 copies/ng total RNA), and pons–medulla oblongata
(4.76 ± 0.40 copies/ng total RNA).
LEVELS OF NMS PEPTIDE IN THE BRAIN OF RATS MAINTAINED UNDER
LIGHT/DARK CYCLING, AND OF FASTED RATS
Most abundant expression of NMS mRNA is found in the
SCN within the brain, and its expression level ﬂuctuates under
light/dark cycling (Mori et al., 2005). Therefore, we measured the
levels of NMS peptide in the hypothalamus, midbrain, and pons–
medulla oblongata of rats during both light and dark periods. The
brains were sampled during the light period at ZT6 and the dark
period at ZT18. In these brain regions, there is no signiﬁcant dif-
ference in peptide levels between groups of rats at ZT6 and ZT18
(Figures 6A–C).
On the other hand, because ICV-administered NMS suppresses
the food intake (Ida et al., 2005), we examined the effect of fasting
on the levels of NMS peptide in the hypothalamus, midbrain, and
pons–medulla oblongata. The peptide levels in the brain regions
tested did not signiﬁcantly differ between groups of free-fed and
48-h fasted rats (Figures 6D–F).
DISCUSSION
We developed a highly sensitive RIA for rat NMS; the lowest detec-
tion limit was 0.25 fmol/tube (equivalent to 10.6 pg/ml). We
evaluated the speciﬁcity of the assay by using a peptide extract
of rat whole brain, because NMS was originally isolated from this
tissue (Mori et al., 2005). The dilution curve for rat brain extract
paralleled the standard curve. Moreover, no immunoreactivity
other than that originating from native (major) and oxidized
(minor) NMS was detected in any of the fractions of extracts
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FIGURE 4 | Expression of neuromedin S (NMS) mRNA in rat brain.
Rat NMS mRNA was quantiﬁed by quantitative reverse transcription–
polymerase chain reaction analysis. The brains were sampled during the
light period. Data represent means ± SEM of three rats.
separated by RP-HPLC, suggesting that the OB1321-2 antiserum
is not cross-reactive to other neuropeptides that are abundantly
expressed in the brain. This is no doubt because NMS shows no
sequence homology with any other known neuropeptide except
for NMU, a structurally related peptide. In addition, this RIA is
unable to detect rat NMU. These data indicate that the assay was
highly speciﬁc.
Within the rat brain, the distribution proﬁle of ir-NMS was
different from that of NMS mRNA. It was interpreted that we
clearly detected NMS peptide in the hypothalamus, because its
mRNA was abundantly expressed in this region. However, we also
detected NMS peptide in the midbrain and pons–medulla oblon-
gata at levels comparable to those in the hypothalamus, whereas
the mRNA levels in these regions were much lower than in the
hypothalamus. Differences in the distributions of the orexin pep-
tide and its mRNA have also been observed. Expression of orexin
mRNA is restricted to the lateral hypothalamic area (LHA) and
posterior hypothalamus (PH; Sakurai et al., 1998), whereas orexin
peptides are distributed in various areas of the brain (Mondal
et al., 1999). Furthermore, immunohistochemical mapping has
shown that orexin-containing nerve ﬁbers are abundant in various
brain areas, including the olfactory bulb, cerebral cortex, thalamus,
hypothalamus, and brainstem (Date et al., 1999). These data indi-
cate that orexin neurons in the LHA or PH send projections widely
across the brain (Date et al., 1999). The predominant expression of
NMS mRNA only in the hypothalamus thus indicates that the cell
bodies of the NMS neurons are located mainly in this region. In
addition, NMS-containing nerve ﬁbers are likely to be present in
the midbrain and pons–medulla oblongata, because NMS peptide
was abundant in these regions despite the low levels of expression
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FIGURE 5 | Expression of neuromedin U receptors types 1 (NMUR1)
and 2 (NMUR2) mRNA in rat brain. Rat NMUR1 (closed bars) and
NMUR2 (open bars) mRNA were quantiﬁed by quantitative reverse
transcription–polymerase chain reaction analysis. Data represent
means ± SEM of three rats.
of NMS mRNA. On the other hand, it is likely that there are fewer
NMS-producing cells in the spinal cord than in the hypothalamus,
because NMS mRNA expression levels are low in the spinal cord,
as they are in the brainstem (Mori et al., 2005). Therefore, it is
likely that nerve ﬁbers originating from hypothalamic NMS neu-
rons project to the brainstem, which consists of midbrain, pons,
and medulla oblongata.
In our previous study, quantitative RT-PCR and in situ
hybridization analyses showed that NMS mRNA was predomi-
nantly expressed in the SCN of the hypothalamus (Mori et al.,
2005), indicating that, within the hypothalamus, most NMS neu-
rons are located in this nucleus. Together with this situation,
in view of the larger distribution in the brain of NMS peptide
compared to NMS mRNA, we speculated the existence of neural
circuits from NMS neurons located in the SCN to the brainstem.
Little is known that the nerve ﬁbers originating from SCN neu-
rons project directly to the brainstem, although it is reported
that the SCN indirectly projects to the locus coeruleus of pons
(Aston-Jones et al., 2001) and the ventral tegmental area of mid-
brain (Luo and Aston-Jones, 2009). The results we described here
may lead to the discovery of novel neural circuits. On the other
hand, another possibility is that NMS peptide in the brainstem
comes from hypothalamic nuclei other than the SCN, such as the
PVN that are known to project to various targets in the brain-
stem (Geerling et al., 2010), whereas the levels of NMS mRNA
in the PVN and other hypothalamic nuclei are extremely low
compared with that in the SCN (Mori et al., 2005). To clarify
these possibilities, immunohistochemical analysis of NMS in the
brain is needed, and further investigation is continued in this
regard.
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FIGURE 6 | Levels of immunoreactive neuromedin S (ir-NMS) in the brain
of rats maintained under light/dark cycling, and of fasted rats. (A–C)
Concentrations of ir-NMS were quantiﬁed in the hypothalamus (A), midbrain
(B), and pons–medulla oblongata (C) of rats under the light at ZT6 and dark at
ZT18. (D–F) Concentrations of ir-NMS were quantiﬁed in the hypothalamus
(D), midbrain (E), and pons–medulla oblongata (F) of free-fed and 48 h-fasted
rats. Data represent means ± SEM of three rats. Data were analyzed
statistically by Student’s t -test.
There are two kinds of receptors for NMS, NMUR1 and
NMUR2 (Brighton et al., 2004; Mori et al., 2005), and their
expression patterns are unique. Expression of NMUR1 is widely
distributed throughout various tissues, and high levels of expres-
sion are found in peripheral tissues (Fujii et al., 2000). In contrast,
NMUR2 mRNA is mainly expressed in the central nervous sys-
tem (Hosoya et al., 2000), and its expression is clearly detected
in the PVN, the wall of the third ventricle in the hypothala-
mus, and the CA1 region of the hippocampus (Howard et al.,
2000). In addition, regional distribution of these receptors in
rat brain was investigated in this study. Quantitative RT-PCR
showed the apparent expression of NMUR2 mRNA in the mid-
brain and pons–medulla oblongata as well as in the hypothalamus.
These data suggest the functional possibility of NMS within the
brainstem.
We and another grouphave demonstrated that ICVadministra-
tion of NMS induces a phase shift in the circadian rhythm (Mori
et al., 2005), suppression of food intake (Ida et al., 2005), reduction
of urine volume (Sakamoto et al., 2007), increased in milk ejection
(Sakamoto et al., 2008), and release of luteinizing hormone (Vigo
et al., 2007). All of actions are induced as a result of the direct
effects of NMS on hypothalamic nuclei such as the SCN, ARC,
PVN, and SON (Ida et al., 2005; Mori et al., 2005; Sakamoto et al.,
2007, 2008; Vigo et al., 2007). On the other hand, NMS peptide
and NMUR2 mRNA are present in the brainstem, suggesting the
physiological role of NMS system in this region. However, the
function of NMS by direct action on the brainstem remains to be
clariﬁed. The brainstem is important for basic bodily functions
(especially regulation of the cardiovascular and respiratory sys-
tems). Therefore, regulation of these systems may be a major role
of NMSwithin the brainstem, although it is not yet certainwhether
this action is a result of a direct effect of NMS in this region. On
the other hand, our group recently reported that, in mice, NMS
regulates the heart rate through the sympathetic nervous system
(Sakamoto et al., 2011).
In the rat brain, NMS mRNA is predominantly expressed in the
SCN, with weak expression in other nuclei of hypothalamus, and
its expression ﬂuctuates within the SCN under light/dark cycling:
the largest decrease occurs during the dark period, followed by a
gradual increase until the late light period (Mori et al., 2005). In
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contrast, there is no difference in hypothalamic content of NMS
peptide between groups of rats during the light and dark periods.
In general, the neuropeptide is stored in the secretory vesicles of
neuron, and released in response to relevant stimuli. In view of
this mechanism, discrepancy between mRNA and peptide levels
of NMS may be caused by mechanism of storage and release of the
neuropeptide as well as differences in mRNA and peptide turnover
rates, because tissue content of peptide is modulated by the pres-
ence or absence of releasing stimuli, even if the expression level of
mRNA is constant. On the other hand, hypothalamic content of
NMS peptide was not inﬂuenced by fasting, although NMS is an
anorexigenic peptide (Ida et al., 2005). To consider the relation-
ship between hypothalamic content of peptide and physiology of
NMS, further investigation is needed.
The negligible detection of NMSpeptide in the spleen and testis
was unexpected, because NMS gene expression levels in these tis-
sues are higher than that in the whole brain (Mori et al., 2005).
Several neuropeptides are produced in the spleen and testis. For
example, somatostatin and itsmRNAaredetected in the spleen and
pituitary adenylate cyclase-activating polypeptide and its mRNA
are detected in the testis, indicating that both neuropeptides are
synthesized and stored until release in these tissues (Aquila et al.,
1991; Shioda et al., 1994). In contrast, because only NMS mRNA
– not its peptide – was detected in the spleen and testis, NMS pep-
tide accumulation is likely to be difﬁcult in these tissues because
NMS may be secreted via constitutive secretory pathways in the
spleen and testis, similar to the way in which adrenomedullin
is secreted from both endothelial and vascular smooth muscle
cells (Sugo et al., 1994a,b). This may occur because the sequences
of the cleavage sites involved in post-translational modiﬁcation
of the NMS precursor coincide with those of the consensus
motifs (Arg-X-Lys/Arg-Arg and Arg-X-Arg-X-X-Arg) for prote-
olytic processing by furin and/or furin-like proteases (proprotein
convertases functioning within constitutive secretory pathways;
Seidah and Chrétien, 1999; Mori et al., 2005). On the other hand,
there is another possible explanation as follows: if NMS mRNA
is highly expressed in a discrete cell population within the spleen
and testis, the peptide gets massively diluted when whole organ is
homogenized. To verify these hypotheses, it is important to iden-
tify the NMS-producing cells in the spleen and testis by in situ
hybridization analysis and immunohistochemistry.
In conclusion, we developed a highly sensitive and highly spe-
ciﬁc RIA for rat NMS. The different distribution of NMS peptide
and its mRNA within the brain suggested the direct projection
of nerve ﬁbers originating from hypothalamic NMS neurons to
the brainstem. In addition, the gene expression of NMS receptor,
NMUR2, was clearly detected in the brainstem. Because the func-
tions of NMS within the brainstem have not yet been identiﬁed,
our ﬁndings provide a foundation on which further research can
build to provide novel insights into the physiological roles of NMS
in the brain.
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